"active-pharmaceutical-ingredient"

Dr Reddy’s Laboratories reported a steep 69% YoY drop in consolidated net profit for Q1 FY27, hit by weak North America sales, lower global generics revenue, and supply disruptions of semaglutide. Shares closed 2.16% lower on the NSE.